Diagnostics
-
Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test
Exact Sciences expects to launch the updated test, which has higher specificity than its predecessor, with Medicare coverage and guideline inclusion in 2025.
By Nick Paul Taylor • Oct. 7, 2024 -
GE Healthcare gets FDA nod for new PET imaging agent
Called Flyrcado, the radiotracer could help improve cardiac imaging accuracy in patients with a high body mass index and women, the company said.
By Susan Kelly • Oct. 1, 2024 -
Trendline
Medical device industry continues to turn to AI
While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.
By MedTech Dive staff -
Top medtech conferences in 2025
The lineup includes industry wide conferences and events covering the latest medtech trends in diabetes, orthopedics, cardiac care and surgical robotics.
By Ricky Zipp • Oct. 1, 2024 -
Congress again delays steep cuts in Medicare lab payments
The American Clinical Laboratory Association welcomed the reprieve but said long-term reform of the Medicare payment system is still needed.
By Susan Kelly • Sept. 26, 2024 -
FDA proposes reclassifying hepatitis B assays
The FDA plans to move the assays from higher-risk class III devices to class II, making them eligible for the 510(k) pathway.
By Nick Paul Taylor • Sept. 26, 2024 -
Roche launches test that detects 12 respiratory viruses
Roche’s TAGS technology allows tests to simultaneously detect multiple respiratory viruses, including influenza A and B, RSV and the COVID-19 virus.
By Nick Paul Taylor • Sept. 25, 2024 -
GE Healthcare wins FDA clearance for Alzheimer’s imaging software
The clearance adds a Centiloid scale tool to GE Healthcare’s Mim software to help clinicians determine the density of amyloid plaque.
By Nick Paul Taylor • Sept. 20, 2024 -
23andMe’s independent board directors resign
In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future.
By Ricky Zipp • Sept. 19, 2024 -
Exact Sciences says data support its colon cancer blood test
Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.
By Susan Kelly • Sept. 16, 2024 -
Inflammatix raises $57M to advance test for infection, sepsis
Inflammatix has now raised over $200 million in private capital, in addition to more than $50 million in grants and contracts.
By Susan Kelly • Sept. 13, 2024 -
J&J leads $50M financing for imaging company Spectrawave
The Series B round will support commercial expansion and product additions for Spectrawave’s system used in the treatment of coronary artery disease.
By Susan Kelly • Sept. 11, 2024 -
Lab group urges lawmakers to rescind FDA final rule on LDTs
A survey found 48% of labs will discontinue LDTs if they do not qualify for an exception under the FDA final rule.
By Nick Paul Taylor • Sept. 9, 2024 -
Illumina court ruling limits EU regulators’ merger review power
The European Commission lacked oversight authority to examine the proposed sale of a cancer-detection company to biotech company Illumina, the court found.
By Justin Bachman • Sept. 9, 2024 -
Diagnostic errors are common. Here are 4 ways to prevent them.
A new, more holistic approach to testing is needed to avoid mistakes that can cause harm, said Marcus Schabacker, CEO of the patient safety group ECRI.
By Susan Kelly • Updated Sept. 11, 2024 -
Illumina avoids fine for Grail purchase in European court victory
Illumina will avoid a penalty of 432 million euros after a court ruled the European Commission did not have jurisdiction to challenge the company’s Grail acquisition.
By Susan Kelly • Sept. 3, 2024 -
Pathology group sues to block FDA lab test rule
The Association for Molecular Pathology is the second lab trade group urging the courts to void an FDA policy expanding oversight of diagnostic tests.
By Susan Kelly • Aug. 30, 2024 -
Qiagen, AstraZeneca expand companion diagnostic pact beyond cancer
The goal is to enable specialty care providers to perform genotyping while patients are undergoing routine clinical examination.
By Nick Paul Taylor • Aug. 29, 2024 -
Illumina wins FDA approval for companion diagnostic cancer test
Physicians can use the test to identify people eligible for treatment with Bayer’s Vitrakvi and Eli Lilly’s Retevmo, which target cancers that have specific genetic features.
By Nick Paul Taylor • Aug. 28, 2024 -
FDA seeks feedback on predetermined change control plans
The guidance describes changes companies can make to medical devices without filing a new 510(k) or premarket approval supplement.
By Nick Paul Taylor • Aug. 26, 2024 -
Roche to increase global laboratory capacity for mpox testing
The World Health Organization has declared an mpox outbreak to be a public health emergency of international concern.
By Nick Paul Taylor • Aug. 26, 2024 -
Quest inks deal for University Hospitals’ outreach lab services
The deal continues Quest’s expansion in Ohio and extends a string of acquisitions that began in May.
By Nick Paul Taylor • Aug. 23, 2024 -
FDA OKs first at-home syphilis test
NowDiagnostics’ over-the-counter test can return results in 15 minutes with a single drop of blood.
By Ricky Zipp • Aug. 19, 2024 -
Routine lab tests fail to detect long COVID in 10,000-person study
Even people with highly symptomatic long COVID may have “no clinically observable objective findings on routine laboratory testing,” according to a study published by the Annals of Internal Medicine.
By Nick Paul Taylor • Aug. 16, 2024 -
Grail to shed 350 workers in restructuring
Less than two months after splitting from Illumina, the liquid biopsy maker is refocusing resources as it pursues an FDA submission for the Galleri multi-cancer early detection test.
By Susan Kelly • Aug. 14, 2024 -
Unilabs inks deal to sell C2N Alzheimer’s blood tests in Europe
C2N Diagnostics announced the partnership after recently receiving an investment from the Japanese drugmaker Eisai, which developed the Alzheimer’s drug Leqembi with Biogen.
By Nick Paul Taylor • Aug. 12, 2024